Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2): S94-S108
DOI: 10.1055/s-2001-18573
Physiology - Metabolism - Pathophysiology

© Johann Ambrosius Barth

Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1,5 diabetes)

G. Schernthaner, S. Hink, H. P. Kopp, B. Muzyka, G. Streit, A. Kroiss
  • Department of Medicine I and Department of Nuclear Medicine, Rudolfstiftung Hospital Vienna, Austria
Further Information

Publication History

Publication Date:
23 November 2001 (online)

Summary:

LADA or type 1.5 diabetes is a slowly progressive form of autoimmune diabetes of adults and represents a considerable proportion (about 5-10%) of all diabetic patients. Associations with high risk HLA genotypes and autoimmune phenomena (GAD, IA2, ICA) show similarities with type 1 diabetes, but phenotypical characteristics of these patients do not allow the correct identification without screening of GAD antibodies. The relatively low antibody titers against islet-cell antigens in LADA patients may be sign of a less aggressive form of autoimmune diabetes and could be responsible for the long non- insulin requirement phase of this diabetes type. Similar as in prediabetic relatives of type 1 diabetic patients the risk for beta cell failure in adult “type 2 diabetic” patients increases with the number of antibodies positive. Consequently, low titers of GAD - in particular in elderly patients - do not predict a progressive and rapid loss of beta-cell failure, when associations with high risk genotypes or other islet-cell antibodies are lacking. Patients with LADA share insulin resistance with type 2 diabetic patients, but display a more severe defect in stimulated beta-cell capacity than patients with classical type 2 diabetes. With respect to features of the metabolic syndrome, patients with LADA have lower BMI, blood pressure and triglyceride levels compared with classical type 2 diabetes patients. Early identification of LADA patients will be mandatory, when effective immune interventions are available for prevention of the beta-cell destructive process and insulin requirement of these patients.

    >